Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €69.84 EUR
Change Today +1.08 / 1.56%
Volume 0.0
As of 3:43 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (82P) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/15 - €106.23
52 Week Low
05/27/14 - €54.73
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PACIRA PHARMACEUTICALS INC (82P)

pacira pharmaceuticals inc (82P) Related Bloomberg News

View More Bloomberg News

pacira pharmaceuticals inc (82P) Related Businessweek News

No Related Businessweek News Found

pacira pharmaceuticals inc (82P) Details

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company’s lead product include, EXPAREL, a liposome injection of bupivacaine, an amide-type anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. It also markets DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. The company’s development pipeline comprises DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical stage for the treatment of acute postsurgical pain; and DepoTranexamic Acid, a pre-clinical phase product for the treatment or prevention of excessive blood loss during surgery by promoting hemostasis. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

445 Employees
Last Reported Date: 02/24/15
Founded in 2006

pacira pharmaceuticals inc (82P) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Head of Technical Op...
Total Annual Compensation: $534.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $503.2K
Chief Medical Officer
Total Annual Compensation: $407.6K
Principal Accounting Officer and Executive Di...
Total Annual Compensation: $288.4K
Compensation as of Fiscal Year 2014.

pacira pharmaceuticals inc (82P) Key Developments

Pacira Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM

Pacira Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: David M. Stack, Chairman, Chief Executive Officer and President.

Pacira Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year of 2015

Pacira Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $58.316 million compared to $36.662 million a year ago. Income from operations was $3.341 million compared to loss of $9.258 million a year ago. Income before income taxes was $1.312 million compared to loss of $11.477 million a year ago. Net income was $1.260 million or $0.03 per basic and diluted share compared to net loss of $11.477 million or $0.34 per basic and diluted share a year ago. Non-GAAP net income was $9.812 million or $0.23 per diluted share compared to net loss of $6.467 million or $0.19 per diluted share a year ago. Adjusted EBITDA was $13.5 million. The company provided earnings guidance for the full year of 2015. The company finished first quarter with cash and investments of approximately $175 million. Looking ahead, they are suspending full year 2015 guidance for EXPAREL revenues, and as a logical consequence, we're also suspending guidance on non-GAAP product gross margins.

Pacira Pharmaceuticals, Inc. to Report Q1, 2015 Results on Apr 30, 2015

Pacira Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on Apr 30, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
82P:GR €69.84 EUR +1.08

82P Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $43.84 USD +0.34
Alkermes PLC $61.35 USD -0.45
Cumberland Pharmaceuticals Inc $6.88 USD +0.08
Durect Corp $2.44 USD +0.10
Halyard Health Inc $41.76 USD -0.29
View Industry Companies

Industry Analysis


Industry Average

Valuation 82P Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.8x
Price/Book 15.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at